The possible potential therapeutic targets for drug induced gingival overgrowth

Gingival overgrowth is a side effect of certain medications. The most fibrotic drug-induced lesions develop in response to therapy with phenytoin, the least fibrotic lesions are caused by cyclosporin A, and the intermediate fibrosis occurs in nifedipine-induced gingival overgrowth. Fibrosis is one o...

Full description

Bibliographic Details
Main Authors: Subramani, Tamilselvan, Rathnavelu, Vidhya, Mohammed Alitheen, Noorjahan Banu
Format: Article
Language:English
Published: Hindawi Publishing Corporation 2013
Online Access:http://psasir.upm.edu.my/id/eprint/28096/
http://psasir.upm.edu.my/id/eprint/28096/1/28096.pdf
_version_ 1848846021682003968
author Subramani, Tamilselvan
Rathnavelu, Vidhya
Mohammed Alitheen, Noorjahan Banu
author_facet Subramani, Tamilselvan
Rathnavelu, Vidhya
Mohammed Alitheen, Noorjahan Banu
author_sort Subramani, Tamilselvan
building UPM Institutional Repository
collection Online Access
description Gingival overgrowth is a side effect of certain medications. The most fibrotic drug-induced lesions develop in response to therapy with phenytoin, the least fibrotic lesions are caused by cyclosporin A, and the intermediate fibrosis occurs in nifedipine-induced gingival overgrowth. Fibrosis is one of the largest groups of diseases for which there is no therapy but is believed to occur because of a persistent tissue repair program. During connective tissue repair, activated gingival fibroblasts synthesize and remodel newly created extracellular matrix. Proteins such as transforming growth factor (TGF), endothelin-1 (ET-1), angiotensin II (Ang II), connective tissue growth factor (CCN2/CTGF), insulin-like growth factor (IGF), and platelet-derived growth factor (PDGF) appear to act in a network that contributes to the development of gingival fibrosis. Since inflammation is the prerequisite for gingival overgrowth, mast cells and its protease enzymes also play a vital role in the pathogenesis of gingival fibrosis. Drugs targeting these proteins are currently under consideration as antifibrotic treatments. This review summarizes recent observations concerning the contribution of TGF-β, CTGF, IGF, PDGF, ET-1, Ang II, and mast cell chymase and tryptase enzymes to fibroblast activation in gingival fibrosis and the potential utility of agents blocking these proteins in affecting the outcome of drug-induced gingival overgrowth.
first_indexed 2025-11-15T08:56:05Z
format Article
id upm-28096
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T08:56:05Z
publishDate 2013
publisher Hindawi Publishing Corporation
recordtype eprints
repository_type Digital Repository
spelling upm-280962016-06-20T06:12:58Z http://psasir.upm.edu.my/id/eprint/28096/ The possible potential therapeutic targets for drug induced gingival overgrowth Subramani, Tamilselvan Rathnavelu, Vidhya Mohammed Alitheen, Noorjahan Banu Gingival overgrowth is a side effect of certain medications. The most fibrotic drug-induced lesions develop in response to therapy with phenytoin, the least fibrotic lesions are caused by cyclosporin A, and the intermediate fibrosis occurs in nifedipine-induced gingival overgrowth. Fibrosis is one of the largest groups of diseases for which there is no therapy but is believed to occur because of a persistent tissue repair program. During connective tissue repair, activated gingival fibroblasts synthesize and remodel newly created extracellular matrix. Proteins such as transforming growth factor (TGF), endothelin-1 (ET-1), angiotensin II (Ang II), connective tissue growth factor (CCN2/CTGF), insulin-like growth factor (IGF), and platelet-derived growth factor (PDGF) appear to act in a network that contributes to the development of gingival fibrosis. Since inflammation is the prerequisite for gingival overgrowth, mast cells and its protease enzymes also play a vital role in the pathogenesis of gingival fibrosis. Drugs targeting these proteins are currently under consideration as antifibrotic treatments. This review summarizes recent observations concerning the contribution of TGF-β, CTGF, IGF, PDGF, ET-1, Ang II, and mast cell chymase and tryptase enzymes to fibroblast activation in gingival fibrosis and the potential utility of agents blocking these proteins in affecting the outcome of drug-induced gingival overgrowth. Hindawi Publishing Corporation 2013 Article PeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/28096/1/28096.pdf Subramani, Tamilselvan and Rathnavelu, Vidhya and Mohammed Alitheen, Noorjahan Banu (2013) The possible potential therapeutic targets for drug induced gingival overgrowth. Mediators of Inflammation, 2013. art. no. 639468. pp. 1-9. ISSN 0962-9351; ESSN: 1466-1861 http://www.hindawi.com/journals/mi/2013/639468/abs/ 10.1155/2013/639468
spellingShingle Subramani, Tamilselvan
Rathnavelu, Vidhya
Mohammed Alitheen, Noorjahan Banu
The possible potential therapeutic targets for drug induced gingival overgrowth
title The possible potential therapeutic targets for drug induced gingival overgrowth
title_full The possible potential therapeutic targets for drug induced gingival overgrowth
title_fullStr The possible potential therapeutic targets for drug induced gingival overgrowth
title_full_unstemmed The possible potential therapeutic targets for drug induced gingival overgrowth
title_short The possible potential therapeutic targets for drug induced gingival overgrowth
title_sort possible potential therapeutic targets for drug induced gingival overgrowth
url http://psasir.upm.edu.my/id/eprint/28096/
http://psasir.upm.edu.my/id/eprint/28096/
http://psasir.upm.edu.my/id/eprint/28096/
http://psasir.upm.edu.my/id/eprint/28096/1/28096.pdf